Question to the Department of Health and Social Care:

To ask His Majesty's Government who are the members of the Refractory Epilepsy Specialist Clinical Advisory Service; and whether they have expertise in relation to the prescription of cannabis-based products for medicinal use.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

The Refractory Epilepsy Specialised Clinical Advisory Service (RESCAS) is a United Kingdom-wide panel of specialist clinicians who provide a clinical advisory service hosted by Great Ormond Street Hospital. The core membership of the RESCAS service is made up of consultant paediatric neurologists, specialist pharmacists, neuroradiologists, neurophysiologists, and genetics specialists.

The RESCAS service provides advice to other clinicians on complex cases of refractory, or drug-resistant, epilepsy. RESCAS supports decisions about treatment options, especially when cases are difficult or outside standard guidance, and provides advice on optimising epilepsy treatment, including the use of complex therapies including cannabinoids. It also provides advice about access to trials and emerging therapies.

The service supports clinical decision-making in situations where conventional treatment pathways have been exhausted, where evidence is limited or emerging, or where novel and non-standard therapies are under consideration. The RESCAS evidence base draws on multiple, complementary sources. These include national guidance and policy frameworks, such as National Institute for Health and Care Excellence guidelines and technology appraisals, NHS England commissioning policies, and relevant regulatory standards. In addition, the service incorporates professional consensus guidance, including specialist input from bodies such as the British Paediatric Neurology Association. This is further strengthened by scientific and clinical evidence, spanning published trials and research across anti-seizure medications, dietary therapies, surgical interventions, and novel or off-label treatments. Together, these components ensure that RESCAS advice reflects both current best practice and emerging developments in epilepsy care.

The Department and NHS England do not hold information on how many National Health Service prescriptions have been made available to children and young people with drug resistant epilepsy as a result of RESCAS advice.

Question to the Department of Health and Social Care:

To ask His Majesty's Government what criteria does the Refractory Epilepsy Specialist Clinical Advisory Service use to make their decisions, and what is its evidence base.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

The Refractory Epilepsy Specialised Clinical Advisory Service (RESCAS) is a United Kingdom-wide panel of specialist clinicians who provide a clinical advisory service hosted by Great Ormond Street Hospital. The core membership of the RESCAS service is made up of consultant paediatric neurologists, specialist pharmacists, neuroradiologists, neurophysiologists, and genetics specialists.

The RESCAS service provides advice to other clinicians on complex cases of refractory, or drug-resistant, epilepsy. RESCAS supports decisions about treatment options, especially when cases are difficult or outside standard guidance, and provides advice on optimising epilepsy treatment, including the use of complex therapies including cannabinoids. It also provides advice about access to trials and emerging therapies.

The service supports clinical decision-making in situations where conventional treatment pathways have been exhausted, where evidence is limited or emerging, or where novel and non-standard therapies are under consideration. The RESCAS evidence base draws on multiple, complementary sources. These include national guidance and policy frameworks, such as National Institute for Health and Care Excellence guidelines and technology appraisals, NHS England commissioning policies, and relevant regulatory standards. In addition, the service incorporates professional consensus guidance, including specialist input from bodies such as the British Paediatric Neurology Association. This is further strengthened by scientific and clinical evidence, spanning published trials and research across anti-seizure medications, dietary therapies, surgical interventions, and novel or off-label treatments. Together, these components ensure that RESCAS advice reflects both current best practice and emerging developments in epilepsy care.

The Department and NHS England do not hold information on how many National Health Service prescriptions have been made available to children and young people with drug resistant epilepsy as a result of RESCAS advice.

Question to the Department of Health and Social Care:

To ask His Majesty's Government how many requests have been made to the Refractory Epilepsy Specialist Clinical Advisory Service since it was established; and how many NHS prescriptions have been made available to children and young people with drug resistant epilepsy as a result of its deliberations since it was established.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

The Refractory Epilepsy Specialised Clinical Advisory Service (RESCAS) is a United Kingdom-wide panel of specialist clinicians who provide a clinical advisory service hosted by Great Ormond Street Hospital. The core membership of the RESCAS service is made up of consultant paediatric neurologists, specialist pharmacists, neuroradiologists, neurophysiologists, and genetics specialists.

The RESCAS service provides advice to other clinicians on complex cases of refractory, or drug-resistant, epilepsy. RESCAS supports decisions about treatment options, especially when cases are difficult or outside standard guidance, and provides advice on optimising epilepsy treatment, including the use of complex therapies including cannabinoids. It also provides advice about access to trials and emerging therapies.

The service supports clinical decision-making in situations where conventional treatment pathways have been exhausted, where evidence is limited or emerging, or where novel and non-standard therapies are under consideration. The RESCAS evidence base draws on multiple, complementary sources. These include national guidance and policy frameworks, such as National Institute for Health and Care Excellence guidelines and technology appraisals, NHS England commissioning policies, and relevant regulatory standards. In addition, the service incorporates professional consensus guidance, including specialist input from bodies such as the British Paediatric Neurology Association. This is further strengthened by scientific and clinical evidence, spanning published trials and research across anti-seizure medications, dietary therapies, surgical interventions, and novel or off-label treatments. Together, these components ensure that RESCAS advice reflects both current best practice and emerging developments in epilepsy care.

The Department and NHS England do not hold information on how many National Health Service prescriptions have been made available to children and young people with drug resistant epilepsy as a result of RESCAS advice.

Question to the Department of Health and Social Care:

To ask His Majesty's Government what role, if any, the Refractory Epilepsy Specialist Clinical Advisory Service has in informing national policies relating to the use of cannabis-based products for medicinal use.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

In 2018, the law was changed to allow specialist doctors to prescribe unlicensed cannabis-based products for medicinal use. This allowed lawful access to these drugs, but did not change how medicines are accessed and funded on the National Health Service.

On the 2 June 2025, the Government asked the Advisory Council on the Misuse of Drugs (ACMD), an independent expert body that advises the Government on drug-related issues, to review the effect of the 2018 law change, to look at whether it has had the desired impact and whether there are any unintended consequences. The ACMD report is expected by summer 2026, and the Government will carefully consider the report and its recommendations before taking any action.

The Government welcomes the input of clinical experts, such as the Refractory Epilepsy Specialist Clinical Advisory Service, in informing policy development.

Question to the Department for Business and Trade:

To ask His Majesty's Government how many inquiries the Competition and Markets Authority are currently undertaking into fraudulent ticket sales for events.

Answered by Lord Leong - Parliamentary Under-Secretary of State (Department for Business, Innovation, Science and Trade)

The Competition and Markets Authority (CMA) does not have powers to investigate criminal fraud, but it has provided supporting evidence for a number of successful criminal prosecutions by National Trading Standards. This includes 4 ticket touts who were sentenced to a combined total of 6 years and 5 months imprisonment in 2024, and two ticket touts sentenced to a total of six-and-a-half years imprisonment in 2020.

The CMA has also taken action using its consumer protection powers against various secondary ticket websites, including ensuring that viagogo and StubHub, the two major platforms in the market, gather key information about tickets from ticket resellers and display it to consumers.

Question to the Department for Business and Trade:

To ask His Majesty's Government how many convictions the Competition and Markets Authority has secured for fraudulent ticket sales for events over the last eight years.

Answered by Lord Leong - Parliamentary Under-Secretary of State (Department for Business, Innovation, Science and Trade)

The Competition and Markets Authority (CMA) does not have powers to investigate criminal fraud, but it has provided supporting evidence for a number of successful criminal prosecutions by National Trading Standards. This includes 4 ticket touts who were sentenced to a combined total of 6 years and 5 months imprisonment in 2024, and two ticket touts sentenced to a total of six-and-a-half years imprisonment in 2020.

The CMA has also taken action using its consumer protection powers against various secondary ticket websites, including ensuring that viagogo and StubHub, the two major platforms in the market, gather key information about tickets from ticket resellers and display it to consumers.

Found: 7 July 2026 Present: Lord Gascoigne (Chair) Baroness Andrews Baroness Barran Lord Bassam of Brighton

Found: Lord Gascoigne (Chair) Baroness Andrews Lord Bailey of Paddington Baroness Barran Lord Bassam of Brighton

Found: am Watch the meeting Members present: Baroness Andrews (in The Chair); Baroness Barran; Lord Bassam of Brighton

Found: Tuesday, 23 June 2026 Present: Baroness Andrews (Chair) Lord Bailey of Paddington Lord Bassam of Brighton

Found: Lord Gascoigne (The Chair); Baroness Andrews; Lord Bailey of Paddington; Baroness Barran; Lord Bassam of Brighton

Found: Lord Gascoigne (The Chair); Baroness Andrews; Lord Bailey of Paddington; Baroness Barran; Lord Bassam of Brighton

Found: London Assembly Housing Committee Committee member, London Assembly Planning Committee Lord Bassam of Brighton

Found: 2026 Present: Lord Gascoigne (Chair) Baroness Andrews Lord Bailey of Paddington Lord Bassam of Brighton

Found: Watch the meeting Members present: Baroness Andrews (The Chair); Lord Bailey of Paddington; Lord Bassam of Brighton

Found: 2026 Present: Lord Gascoigne (Chair) Baroness Andrews Lord Bailey of Paddington Lord Bassam of Brighton

Found: 2026 Present: Lord Gascoigne (Chair) Baroness Andrews Lord Bailey of Paddington Lord Bassam of Brighton

Found: Members present: Lord Gascoigne (The Chair); Baroness Andrews; Lord Bailey of Paddington; Lord Bassam of Brighton

Found: Westminster Present: Lord Gascoigne (Chair) Baroness Andrews Lord Bailey of Paddington Lord Bassam of Brighton

Found: London Assembly Housing Committee Committee member, London Assembly Planning Committee Lord Bassam of Brighton

Found: Letter dated 15/06/2026 from Baroness Twycross to Lord Bassam of Brighton regarding a question raised

No description available